marketNovember 17, 2026
Isomorphic Labs raises $5B for AI-driven drug development

Isomorphic Labs, a company owned by Alphabet, has closed a $5 billion Series C round. The round was led by Greenoaks and Sequoia Capital. The valuation of the developer of AI systems for drug creation came to about $50 billion.
The funds will go toward developing the IsoDDE platform and the company's own drugs against cancer and immune diseases. The company's developments are still at the preclinical stage.